A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
This record was last updated August 6, 2024 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
A prospective, multicenter clinical study designed to explore the efficacy of adaptive therapy based on MRD status in patients with stage II-III non-small cell lung cancer(NSCLC) after treatment. Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-23.